Product Description
Mechanisms of Action: No Mechanism
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Schiffler Cancer Center
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT00247312 | P3 |
Completed |
Prostate Cancer |
2015-11-01 |
|
| NCT00241384 | P3 |
Completed |
Prostate Cancer |
2015-11-01 |
|
| 02-4407-V04 | P3 |
Unknown status |
Prostate Cancer |
None |
|
| NCT00494546 | P3 |
Completed |
Prostate Cancer |
None |